Apomorphine is a novel necroptosis inhibitor targeting mixed lineage kinase domain-like protein oligomerization
8.5
来源：
Nature
关键字：
ML brain science
发布时间：
2025-10-13 19:32
摘要：
Apomorphine (APO), an FDA-approved drug for Parkinson's disease, has been identified as a novel necroptosis inhibitor targeting mixed lineage kinase domain-like protein (MLKL) oligomerization. This study demonstrates that Ox-APO, the oxidized form of APO, effectively inhibits necroptosis in murine models of inflammatory bowel disease and liver injury. The findings suggest that Ox-APO could serve as a promising candidate for treating necroptosis-related diseases, highlighting its potential for broader therapeutic applications.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+重点关注领域符合度
business_impact
0.8分+商业影响力
scientific_rigor
1.5分+数据支撑的科学性
timeliness_innovation
1.5分+时效性与创新性
investment_perspective
2.5分+BOCG投资视角
market_value_relevance
1.0分+市场价值相关性
team_institution_background
0.5分+团队与机构背景
technical_barrier_competition
0.7分+技术壁垒与竞争格局
关键证据
Ox-APO significantly ameliorated tissue damage in two murine necroptosis models.
APO was found to inhibit necroptosis by blocking MLKL oligomerization.
Ox-APO showed stronger binding to MLKL than the reduced form of APO.
真实性检查
否
AI评分总结
Apomorphine (APO), an FDA-approved drug for Parkinson's disease, has been identified as a novel necroptosis inhibitor targeting mixed lineage kinase domain-like protein (MLKL) oligomerization. This study demonstrates that Ox-APO, the oxidized form of APO, effectively inhibits necroptosis in murine models of inflammatory bowel disease and liver injury. The findings suggest that Ox-APO could serve as a promising candidate for treating necroptosis-related diseases, highlighting its potential for broader therapeutic applications.